Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Epidarex Capital is a transatlantic venture capital firm founded to invest in early-stage, high-growth life science and health technology companies. Established with a dual presence in the United Kingdom and the United States, Epidarex aims to build companies in emerging and under-ventured research hubs. The firm provides equity capital to startups, including university spin-outs, leveraging its extensive scientific and industry networks to identify transformative investments. Epidarex Capital is recognized for its commitment to partnering with scientists and entrepreneurs to develop innovative products that address critical needs in the global healthcare market.
Since its inception, Epidarex has focused on creating value through strategic investments in the life sciences sector. The firm has successfully raised multiple funds, with the recent closing of Fund IV at $145 million, which underscores its strong financial backing and commitment to supporting the next wave of life science startups. Epidarex's reputation is built on its ability to navigate complex scientific landscapes and its dedication to fostering innovation in healthcare.
Epidarex Capital specializes in early-stage life science opportunities, particularly in the fields of biotechnology, pharmaceuticals, medical devices, and health technology. The firm strategically targets emerging research hubs in both the United States and the United Kingdom, often collaborating with leading universities and research institutions to identify and develop groundbreaking innovations. Epidarex's investment strategy includes providing seed or Series A funding to spin out innovations from medical research universities, which allows them to capitalize on cutting-edge research and technology.
The firm evaluates potential investments based on several key criteria, including the presence of disruptive technologies that address unmet medical needs, sustainable competitive advantages, robust intellectual property, and early traction from key opinion leaders in the industry. By focusing on these areas, Epidarex aims to support companies that have the potential to make significant impacts in the healthcare sector, ultimately improving patient outcomes and advancing medical science.
Epidarex Capital boasts a diverse portfolio of notable companies that exemplify its commitment to investing in transformative life science innovations. Among its prominent investments are:
This diverse portfolio reflects Epidarex's strategic focus on high-potential companies that are positioned to lead advancements in healthcare and biotechnology.
To pitch Epidarex Capital, founders should email info@epidarex.com. It is recommended to include a detailed overview of the business, highlighting the technology, market opportunity, and team qualifications. Warm introductions are preferred, but cold applications are also accepted.
Recently, Epidarex Capital has been active in announcing significant developments within its portfolio. Notable updates include Lario Therapeutics receiving $2.4 million from The Michael J. Fox Foundation, and Harness Therapeutics nominating a first-in-class drug candidate for Huntington’s Disease. Additionally, they announced the first close of Fund IV, securing $145 million to support the next wave of life science start-ups.
Epidarex Capital primarily invests in early-stage companies, focusing on seed and Series A funding rounds. This allows them to support startups at critical points in their development, helping to bring innovative life science solutions to market.
Founders can pitch Epidarex Capital by sending an email to info@epidarex.com. It is advisable to provide a clear overview of the business, including the technology, market opportunity, and team background.
Epidarex Capital focuses on the life sciences sector, particularly in biotechnology, pharmaceuticals, medical devices, and health technology. They are particularly interested in companies that are developing disruptive technologies that address unmet medical needs.
While specific check sizes are not detailed, Epidarex Capital typically provides seed and Series A funding, which generally ranges from several hundred thousand to a few million dollars, depending on the stage and needs of the startup.
Epidarex Capital invests in both North America and Europe, with a particular focus on emerging research hubs in these regions. This transatlantic approach allows them to leverage diverse scientific and industry networks.
To apply for funding, founders should reach out via email at info@epidarex.com. Providing a well-structured pitch that outlines the business model, technology, and market potential is crucial for consideration.
Epidarex Capital actively engages with its portfolio companies, offering strategic guidance and leveraging its extensive network in the life sciences sector to support growth and development. This includes access to industry experts and potential partnerships.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.